A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations

A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations

The Pew Charitable Trusts held a one-day conference, “A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations” on Thursday, January 31, 2013.

As multidrug-resistant infections have grown more prevalent, few new antibiotics are reaching the market. This is attributed, in part, to the economic and regulatory challenges associated with their development. Recently, stakeholders have endorsed a novel regulatory pathway to approve these lifesaving drugs for use in limited patient populations — namely those at highest risk and with few or no other options. Leaders representing the drug industry, health care providers, government regulators and payors came together to advance this concept and explore its feasibility from a business and public health perspective.

The Pew Charitable Trusts makes every effort to comply with federal, state and local government ethics rules when hosting events. Please make sure that your participation is consistent with applicable ethics rules.

National Homeownership Month

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.